Files
Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/194119
Epigenetic reprogramming of tumor-associated fibroblasts in lung cancer: therapeutic opportunities
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Lung cancer is the leading cause of cancer-related death worldwide. The desmoplastic stroma of lung cancer and other solid tumors is rich in tumor-associated fibroblasts (TAFs) exhibiting an activated/myofibroblast-like phenotype. There is growing awareness that TAFs support key steps of tumor progression and are epigenetically reprogrammed compared to healthy fibroblasts. Although the mechanisms underlying such epigenetic reprogramming are incompletely understood, there is increasing evidence that they involve interactions with either cancer cells, pro-fibrotic cytokines such as TGF-β, the stiffening of the surrounding extracellular matrix, smoking cigarette particles and other environmental cues. These aberrant interactions elicit a global DNA hypomethylation and a selective transcriptional repression through hypermethylation of the TGF-β transcription factor SMAD3 in lung TAFs. Likewise, similar DNA methylation changes have been reported in TAFs from other cancer types, as well as histone core modifications and altered microRNA expression. In this review we summarize the evidence of the epigenetic reprogramming of TAFs, how this reprogramming contributes to the acquisition and maintenance of a tumor-promoting phenotype, and how it provides novel venues for therapeutic intervention, with a special focus on lung TAFs.
Subject (English)
Citation
Citation
ALCARAZ CASADEMUNT, Jordi, et al. Epigenetic reprogramming of tumor-associated fibroblasts in lung cancer: therapeutic opportunities. Cancers. 2021. Vol. 13, num. 15, pags. 3782-3802. ISSN 2072-6694. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/194119